The Peter Attia Drive 2024年07月23日
#267 ‒ The latest in cancer therapeutics, diagnostics, and early detection | Keith Flaherty, M.D.
index_new5.html
../../../zaker_core/zaker_tpl_static/wap/tpl_guoji1.html

 

本期节目邀请到了麻省总医院癌症中心的临床研究主管Keith Flaherty,深入探讨了癌症随着年龄增长的发生率,强调了寻找有效治疗和早期检测方法的重要性。他回顾了癌症治疗方法的历史,并详细介绍了过去十年中癌症治疗的显著进步,特别是免疫疗法和对抗癌症逃避策略的疗法,同时指出了特异性、成本和可扩展性方面的挑战。此外,Keith还提到了早期检测方法的重大飞跃,尤其是液体活检,它不仅能早期发现癌症,还能确定可能的组织来源。

🔍Keith Flaherty分享了癌症与年龄增长的统计数据,强调了早期发现和治疗的重要性,并回顾了癌症治疗的历史和近期进展。

🧬免疫疗法潜力巨大,能够对抗癌症的逃避机制,但面临特异性、成本和规模化挑战。

🔬液体活检作为早期检测手段,能确定癌症的存在和可能的组织来源,为早期干预提供了新希望。

🤕治疗转移性癌症的挑战突显了早期检测的重要性,以提高生存率。

🌟未来五年内,癌症治疗可能的发展方向包括T细胞激活、代谢干预、靶向肿瘤微环境等。

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

Keith Flaherty is the director of clinical research at the Massachusetts General Hospital Cancer Center and a previous guest on The Drive. In this episode, Keith first delves into the statistics on cancer's prevalence as we age, underscoring the significance of finding effective treatments and early detection methodologies. He touches on the history of cancer therapeutics and illuminates the notable enhancements in cancer therapy within the last decade that are setting the stage for a promising future. He goes into detail on the potential of immunotherapy and therapies that can combat cancer’s evasive tactics while explaining some of the existing challenges around specificity, cost, and scalability. Additionally, Keith highlights the significant leap in early detection methodologies, namely liquid biopsies, which have the potential not only to determine if a cancer is present in an early stage, but also identify the possible tissue of origin.

We discuss:

Connect With Peter on TwitterInstagramFacebook and YouTube

Fish AI Reader

Fish AI Reader

AI辅助创作,多种专业模板,深度分析,高质量内容生成。从观点提取到深度思考,FishAI为您提供全方位的创作支持。新版本引入自定义参数,让您的创作更加个性化和精准。

FishAI

FishAI

鱼阅,AI 时代的下一个智能信息助手,助你摆脱信息焦虑

联系邮箱 441953276@qq.com

相关标签

癌症治疗 免疫疗法 液体活检 早期检测 治疗进展
相关文章